Scancell Share Discussion Threads

[gazza] 08/2/2021 23:00

NK, Still 4 days to go, can't wait for the 30/40p you predicted!

[gazza] 08/2/2021 22:57

DC, So long as you're not using my money, I couldn't care less.

[supernumerary] 08/2/2021 20:40

I think it's good that you're thinking first.

[dominiccummings] 08/2/2021 20:24

I'm thinking of buying more of these in the morning.... any thoughts?

[bermudashorts] 08/2/2021 19:54

Cool thanks gooosed and also to you Albert Arthur for the Janet Daly heads up.

[albert arthur] 08/2/2021 19:39

Welcome bud, it's easier to post shots, videos etc. Also coded the RNS to stream there in python. I like to use both :) cheers

[gooosed] 08/2/2021 19:34

May be of interest :

"DIARECT, part of BBI Solutions, has newly developed SARS-CoV-2 Nucleocapsid (N) Protein and #SARSCoV2 Spike (S) Glycoprotein, outperforming reference antigens (manufactured in different expression systems) in different serological #assays. Learn more "

[ivyspivey] 08/2/2021 19:26

Agree Bermuda she us definitely talking about SN 14 as she specifically mentions other proteins rather than the Spike

[bermudashorts] 08/2/2021 19:21

Yes it does.

[miavoce] 08/2/2021 19:11

Thanks for the link Albert I have joined the group. Certainly does appear to be Covidity she is referring to.

[albert arthur] 08/2/2021 18:49

Video in this TG group:https://t.me/joinchat/RWLQ9O_RqKn9f_7I

[albert arthur] 08/2/2021 18:44

Janet Daly on Sky now, subtly talking about our vaccine..

[geckotheglorious] 08/2/2021 16:32

J777J
Post 36569
Did you read beyond the headline?

"Oxford Covid vaccine has 10% efficacy against South African variant, study suggests. Small-scale trial of vaccine shows it offers very little protection against mild to moderate infection"

"Scientists who conducted a small-scale trial of the vaccine’s efficacy said it showed very little protection against mild to moderate infection, though they expressed hope that – in theory – it would still offer significant protection against more serious infection"

So key is:
1) Does it prevent hospitalisation, so worthwhile still!
2) Does it prevent serious infection, would still be worthwhile therefore.

3) Small scale trial.
How small?

4) Whilst it may have low efficacy for the younger people (in this small scale trial) what is its efficacy for those aged over 60???

Wouldn't write it off so soon.

[bermudashorts] 08/2/2021 15:01

Have you seen the confidence interval levels? The 10% figure is pretty meaningless.

As clear a demonstration as you'll ever see of the value (or lack of) of an underpowered clinical trial in young and healthy patients that ends up telling you virtually nothing new and creates more questions than it answers.

It was already known from the J&J trial that efficacy against the South African mutation is much reduced and the AZN trial is following the same pattern. The issue here is that the trial wasn't designed or powered to give any information on efficacy against severe cases or death. Although there were no cases of either on the trial, the patient demographic means that you can't draw any conclusions at all from the data. A wasted opportunity for the Oxford vax and I'm sure AZN would have run a completely different trial.

Perhaps we're seeing the difference in scale of development between academia and big pharma which is exactly why it would be good to see Scancell partner asap after phase I.

IMO

[j777j] 08/2/2021 13:21

10% is worthless

[j777j] 08/2/2021 13:21

https://www.google.com/amp/s/amp.theguardian.com/world/2021/feb/08/oxford-covid-vaccine-10-effective-south-african-variant-study

[gooosed] 08/2/2021 12:38

Interesting thread :

[oldnotwise] 08/2/2021 08:01

13.6/14.175
Bid now 13.925

[gooosed] 07/2/2021 17:09

“Efforts are under way to develop a new generation of vaccines that will allow protection to be redirected to emerging variants as booster jabs, if it turns out that it is necessary to do so,” said Sarah Gilbert, a professor of vaccinology at the University of Oxford.

“We are working with AstraZeneca to optimise the pipeline required for a strain change should one become necessary. This is the same issue that is faced by all of the vaccine developers, and we will continue to monitor the emergence of new variants that arise in readiness for a future strain change.”

Gilbert told The Andrew Marr Show that her team had “a version with the South African spike sequence in the works”. She said: “It’s not quite ready to vaccinate people with yet, but as all of the developers are using platform technologies, these are ways of making a vaccine that are very quick to adapt.

“It looks very much like it will be available for the autumn.”"

[dominiccummings] 07/2/2021 10:29

#36560 Much of what was done to make the vaccine project a reality was done 'at risk'. i.e. money was spent or committed without knowing whether the funds could be recovered.
AZ are the project owner because they bring the financial strength and the international connections to make worldwide distribution a reality.

[albert arthur] 07/2/2021 10:13

Oxford/AstraZeneca jab fails to prevent mild and moderate Covid from S African strain, study showshttps://amp.ft.com/content/e9bbd4fe-e6bf-4383-bfd3-be64140a3f36?segmentid=acee4131-99c2-09d3-a635-873e61754ec6&__twitter_impression=true

[inanaco] 06/2/2021 16:03

yep ... Sanofi/gsk thought they were big

AstraZ what did they develop ? the syringe